Does an ablate and pace strategy improve outcomes and quality of life in highly symptomatic patients with permanent atrial fibrillation refractory to pharmacologic therapy?
An ablate and pace strategy improves quality of life and reduces symptoms in highly symptomatic patients with permanent atrial fibrillation, despite similar long-term declines in LVEF and NYHA class compared to the control group.
In this long-term follow-up of the AIRCRAFT cohort, similar decline in LVEF and NYHA class was observed in both treatment groups. AVJAP patients have better quality of life with fewer symptoms. Based on improved quality of life, ablate and pace strategy for permanent atrial fibrillation should be considered for highly symptomatic patients refractory to pharmacologic therapy.
Lim et al. (Wed,) studied this question.